A.S. KURAKINA², N.A. SHCHELCHKOVA¹, I.V. MUKHINA¹, V.N. GRIGORYEVA¹

 ¹Privolzhsky Research Medical University of the Ministry of Health of the Russian Federation, Nizhny Novgorod

²Perm State Medical University named after Academician E.A. Wagner of the Ministry of Healthcare of the Russian Federation, Perm

 Contact details:

Kurakina A.S. — Assistant Lecturer of the Department of Neurology and Medical Genetics

Address: 26 Petropavlovskaya St., Russian Federation, Perm, 614000, tel.: +7-910-796-69-92, e-mail: [email protected]

 The purpose was to study the diagnostic value of the content of brain-derived neurotrophic factor (BDNF) and glial-derived neurotrophic factor (GDNF) in patients with meningiomas before and after surgery.

Material and methods. The study involved 70 patients with meningiomas and 62 healthy people. The examination of the patients included clinical and neurological examination, determination of BDNF and GDNF (R&D Systems, USA) content in blood plasma using enzyme immunoassay performed before the surgery and 5–6 days after meningioma surgery. The totality of meningioma removal was determined intraoperatively, which was then confirmed by control neuroimaging a day after the operation.

Results. BDNF level less than 2038,6 PG/ml allows diagnosing the characteristic of meningiomas changes with a sensitivity of 88% and a specificity of 44%. GDNF level more than 3.1 PG/ml allows diagnosing the meningioma-related changes in the brain with sensitivity of 84% and specificity of 51%. The plasma level of BDNF in patients after subtotal removal of meningioma on 5–6 days after surgery significantly increased, compared with the preoperative value, p = 0,01. The plasma concentration of GDNF in patients with meningiomas after radical removal of the tumor significantly decreased compared to its preoperative lever, p = 0,01. Conclusion. To summarize, our data show that none of the investigated markers is suitable to substitute histological diagnosis. However, measurement of circulating BDNF and GDNF before and after surgery may be a support to diagnose the totality of meningioma removal.

Key words: brain-derived neurotrophic factor, glial cell-derived neurotrophic factor, meningioma.

  REFERENCES

1. Krylov V.V. Lektsii po neyrokhirurgii [Lectures on neurosurgery]. Moscow: KMK, 2008. 280 p.
2. Yamamoto J., Takahashi M., Idei M. et al. Clinical features and surgical management of intracranial meningiomas in the elderly. Oncol Lett, 2017, vol. 14 (1), rr. 909–917.
3. Tigliev G.S., Olyushin V.E., Kondrat’ev A.N. Vnutricherepnye meningiomy [Intracranial meningiomas]. Saint Petersburg: Izd-vo RNKhI im. prof. A.L. Polenova, 2001. 560 p.
4. Vedunova M.V., Terent’eva K.A., Shchelchkova N.A. Diagnostic value of determining the concentration of neurotrophic factors and neuron-specific enolase in the blood of newborns with CNS disorders. STM, 2015, vol. 7, no. 2, pp. 25–32 (in Russ.).
5. Vorob’eva E.N., Shumakher G.I., Serikova I.Yu. Laboratory markers of long-term consequences of perinatal CNS damage in adolescents. Journal of Siberian Medical Sciences, 2013, no. 2, pp. 1–6 (in Russ.).
6. Astrakhanova T.A., Urazov M.D., Usenko A.V. BDNF-mediated regulation of the functional state of the mitochondria of brain cells under conditions of hypoxia. STM, 2018, vol. 10, no. 3, pp. 88–94 (in Russ.).
7. Rahman M., Luo H., Sims N.R. et al. Investigation of Mature BDNF and proBDNF Signaling in a Rat Photothrombotic Ischemic Model. Neurochemical Reserch, 2018, vol. 43 (3), rr. 637–649.
8. Fantacci C., Capozzi D., Ferrara P., Chiaretti A. Neuroprotective Role of Nerve Growth Factor in Hypoxic-Ischemic Brain Injury. Brain Sciences, 2013, vol. 3 (3), pp. 1013–1022.
9. Shchelchkova N.A., Mitroshina E.V., Mukhina I.V. The adaptive role of the glial neurotrophic factor in cerebral ischemia. Sovremennye tekhnologii v meditsine, 2017, vol. 9, no. 1, pp. 68–77 (in Russ.).
10. Artico M., Bronzetti E., Pompili E. et al. Immunohistochemical profile of neurotrophins in human cranial dura mater and meningiomas. Oncology Reports, 2009, vol. 21 (6), pp. 1373–1380.
11. Hilton D.A., Shivane A., Kirk L. et al. Activation of multiple growth factor signalling pathways is frequent in meningiomas. Neuropathology, 2016, vol. 36 (3), pp. 250–261.
12. Perry A., Lusis E.A., Gutmann D.H. Meningothelial hyperplasia: a detailed clinicopathologic, immunohistochemical and genetic study of 11 cases. Brain Pathol, 2005, vol. 15 (2), pp. 109–115.
13. Ilhan-Mutlu A., Wagner L., Widhalm G. et al. Exploratory investigation of eight circulating plasma markers in brain tumor patients. Neurosurgical review, 2013, vol. 36 (1), pp. 45–55.
14. Ildan F., Erman T., Göçer A.I. et al. Predicting the probability of meningioma recurrence in the preoperative and early postoperative period: a multivariate analysis in the midterm follow-up. Skull Base, 2007, vol. 17 (3), pp. 157–171.
15. Konovalov A.N., Kozlov A.V., Cherekaev V.A. et al. The problem of meningiomas: analysis of 80-year-old material from the Institute of Neurosurgery. N.N. Burdenko and prospects. Voprosy neyrokhirurgii, 2013, vol. 77, no. 1, pp. 12–23 (in Russ.).
16. Airaksinen, M.S., Saarma M. The GDNF family: signalling, biological functions and therapeutic value. Nat Rev Neurosci, 2002, vol. 3 (5), pp. 383–394.
17. Roslavtseva V.V., Salmina A.B., Prokopenko S.V. Possibilities of using the neurotrophic factor of the brain as a marker of the effectiveness of therapy in degenerative, traumatic and ischemic brain damage. Nevrologicheskiy zhurnal, 2015, vol. 20, no. 2, pp. 38–46 (in Russ.).
18. Kurakina A.S., Grigor’eva V.N., Mukhina I.V. Prognostic value of neurotrophic factors and neuron-specific enolase in patients with extracerebral brain tumors. STM, 2014, vol. 6, no. 3, pp. 6–13 (in Russ.).